Table 2 Characteristics of the immunosuppressed patients (IS-VL) at the time of VL diagnosis
Sex, age (years) | Underlying disease | Origin | Time between starting immunosuppression and VL diagnosis | Corticosteroids (CE)a | Methotrexate | Anti-TNF | Others |
|---|---|---|---|---|---|---|---|
Female, 68 | RA | Spain | > 1 year | CE, low | Methotrexate | No | No |
Male, 50 | IBD | Spain | 4 months | CE, intermediate | No | No | No |
Male, 88 | COPD | Spain | > 1 year | CE, high | No | No | No |
Male, 64 | Psoriatic arthritis | Spain | > 1 year | No | Methotrexate | No | No |
Male, 40 | UIP | Spain | > 1 year | CE, intermediate | No | No | Azathioprine |
Female, 54 | RA | Spain | > 1 year | CE, intermediate | Methotrexate | Etanercept | No |
Female, 69 | RA | Cuba | 4 months | CE, intermediate | Methotrexate | No | No |
Male, 54 | Psoriatic arthritis | Spain | Mtx > 1 year, Eta 10 months | CE, low | Methotrexate | Etanercept | No |
Male, 65 | COPD | Spain | > 1 year | CE, high | No | No | No |
Female, 44 | IBD | Spain | > 1 year | No | No | Infliximab | Azathioprine |
Female, 60 | RA | Spain | > 1 year | No | Methotrexate | No | IL-20 |
Female, 47 | IBD | Spain | 16 months | No | No | Adalimumab | No |
Female, 44 | Psoriasis | Spain | > 1 year | No | Methotrexate | No | No |
Male, 72 | Giant-cell arteritis | Spain | > 1 year | CE, high | No | No | No |
Male, 33 | Tubulo-interstitial nephritis | Nigeria | 5 months | CE, high | No | No | No |
Male, 30 | IgA nephropathy | Spain | > 1 year | CE, low | No | No | No |